Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracranial Progression-Free Survival Correlates with Overall Survival and Varies by Tumor Subtype in Patients with Breast Cancer and Brain Metastases.

Neuro-oncology·2026
Same author

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.

NPJ precision oncology·2026
Same author

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Impact of systemic therapy after stereotactic radiosurgery in patients with limited brain-only metastasis.

Neuro-oncology advances·2026
Same author

The American Journal of Pathology and the American Society for Investigative Pathology: Forging the Next Century of Insights into Mechanisms of Disease.

The American journal of pathology·2025
Same author

Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative.

Neuro-oncology·2025

Related Experiment Video

Updated: Feb 24, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Discerning Clinical Responses in Breast Cancer Based On Molecular Signatures.

William B Coleman1, Carey K Anders2

  • 1Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; UNC Program in Translational Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; UNC Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina.

The American Journal of Pathology
|August 21, 2017
PubMed
Summary

Breast cancer subtypes, identified by molecular signatures, offer insights into disease behavior and treatment response. These classifications aid in predicting patient outcomes and guiding personalized breast cancer treatment strategies.

More Related Videos

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

1.3K
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

7.1K

Related Experiment Videos

Last Updated: Feb 24, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

1.3K
Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

7.1K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Breast cancer exhibits significant heterogeneity in clinical behavior and treatment response, despite similar histopathological features.
  • Molecular profiling has revealed distinct intrinsic subtypes (luminal A, luminal B, HER2-enriched, basal-like) with varying aggressiveness.

Purpose of the Study:

  • To review the molecular classification of breast cancer.
  • To discuss the application of predictive and prognostic molecular signatures in guiding treatment decisions.

Main Methods:

  • Analysis of gene expression patterns to identify molecular subtypes.
  • Review of existing literature on molecular signatures for breast cancer prediction and prognostication.

Main Results:

  • Identification of four intrinsic molecular subtypes of breast cancer.
  • Association of subtypes with clinical aggressiveness, though not perfectly predictive of outcomes.

Conclusions:

  • Molecular classification refines understanding of breast cancer heterogeneity.
  • Predictive/prognostic molecular signatures are crucial tools for personalized treatment strategies in breast cancer management.